尤瑞克林治疗急性大灶脑梗死的临床研究  

Urinary kallidinogenase in treatment of acute cerebral infarction

作　　者：商旭华 

机构地区：[1]上蔡县人民医院神经内科一病区,驻马店463800

出　　处：《国际医药卫生导报》2017年第19期3056-3058,共3页International Medicine and Health Guidance News

摘　　要：目的观察尤瑞克林治疗急性大灶脑梗死的临床疗效。方法选取本院神经内科2014年7月至2016年11月收治的急性大灶脑梗死患者60例，根据随机数表法分为对照组及观察组，各30例。对照组实施常规治疗；观察组在对照组基础上加用尤瑞克林治疗。治疗1个月后，观察并比较两组疗效及安全性。结果观察组病死率低于对照组，差异有统计学意义（P〈0．05）；治疗后，观察组脑梗死病灶体积小于对照组，美国国立卫生研究院卒中量表（National Institute of Healthstrokescale，NIHSS）评分低于对照组，差异有统计学意义（P〈0．05）；两组治疗过程中均无明显不良反应。结论尤瑞克林治疗急性大灶脑梗死，患者脑梗死体积明显缩小，神经功能缺损改善好，无明显不良反应，用药安全性高。Objective To observe the clinical effect urinary kallidinogenase in treatment of acute cerebral infarction. Methods 60 patients with acute large cerebral infarction treated at our department from July, 2014 to November, 2016 were selected and randomly divided into a control group and an observation group, 30 cases for each group. The control group were routinely treated; in addition, the observation group were treated with urinary kallidinogenase. 1 months after the treatment, the efficacy and safety of the two groups were observed and compared. Results The mortality and the score of National Institute of Health stroke scale（NIHSS） were lower in the observation group than in the control group, with statistical differences （P 〈 0.05）. No obvious adverse reactions occurred in the two groups during the treatment. Conclusion Urinary kallidinogenase in the treatment of acute cerebral infarction can significantly reduce the volume of cerebral infarction and improve neurological deficits and has no obvious adverse reactions and is safe.

关 键 词：急性大灶脑梗死 尤瑞克林 疗效 安全性 

分 类 号：R743.3[医药卫生—神经病学与精神病学]